Browse the evidence

Mutations in the LGR4 gene, specifically the A750T variant, are associated with increased obesity risk, central obesity, and metabolic complications in humans, and ablation of Lgr4 in mice resists diet-induced obesity by promoting browning of visceral white adipose tissue.

Genetic variations in the LGR4 gene can predispose individuals to central obesity and metabolic issues. In mice, removing this gene prevents obesity by promoting the browning of fat, which burns energy. This suggests that targeting the LGR4 pathway could be a potential therapeutic strategy for treating obesity and its complications.

Government-imposed confinement and mobility restrictions during the COVID-19 pandemic caused a significant decrease in Health-Related Quality of Life (HRQoL) among pregnant women, primarily driven by increased anxiety, depression, and pain.

Confinement can significantly lower your quality of life during pregnancy, increasing anxiety and pain. To mitigate this, seek online support for childbirth preparation and maintain communication with healthcare providers to address fears of contagion.

Government-imposed confinement and mobility restrictions during the COVID-19 pandemic did NOT significantly alter the adherence to the Mediterranean Diet among pregnant women.

Contrary to fears, confinement did not necessarily ruin dietary habits for these pregnant women. If you already follow a healthy diet, you may be able to maintain it during restrictions.

GLP-1 receptor stimulation reduces alcohol consumption and reward, particularly in individuals with high baseline alcohol intake, by acting on the mesolimbic system.

For individuals with high alcohol consumption, GLP-1 based therapies may reduce the desire to drink by lowering the reward value of alcohol. This effect is most prominent in those who drink heavily. While current approvals are for diabetes/obesity, this mechanism suggests potential future use in alcohol use disorder, particularly for heavy drinkers.

The combination of earplugs, eye masks, and relaxing music significantly improves subjective sleep quality in ICU patients, but does not significantly alter nocturnal melatonin or cortisol levels compared to routine care.

For ICU patients, using earplugs, eye masks, and 30 minutes of relaxing music before bed can help them feel they slept better. However, do not expect this to fix stress hormone levels (cortisol/melatonin), as surgery and medications likely override these biological markers. Ensure patients are comfortable with the devices to avoid refusal.

Encapsulation techniques (e.g., spray drying, coacervation) protect probiotics from environmental stressors (heat, acid, oxidation) during production, storage, and gastrointestinal transit.

Look for probiotic products that mention 'encapsulation' or 'delayed release.' This technology helps the bacteria survive stomach acid so they can reach your intestines where they are needed.

A 'Behavioral Justice' framework, which combines individual responsibility with societal responsibility to provide health-promoting environments, is the optimal approach to reducing obesity.

Policymakers should implement 'Behavioral Justice' by ensuring all communities have access to healthy food and safe exercise spaces. This does not absolve individuals of responsibility but makes it possible for them to exercise it. Both individual action and systemic change are required.

Gut microbiota composition influences obesity risk through energy harvesting efficiency, specifically via the Firmicutes-to-Bacteroidetes ratio and short-chain fatty acid (SCFA) production.

Focus on dietary diversity and fiber intake to support a healthy gut microbiome. While not a magic bullet, a diet rich in prebiotics and probiotics may help regulate energy balance and reduce obesity risk by influencing gut bacteria composition.

Short-chain fatty acids (SCFAs) produced by gut microbiota influence host energy homeostasis and adipose storage through multiple mechanisms including GPCR signaling and histone deacetylase inhibition.

Increase your intake of fiber-rich foods (vegetables, fruits, whole grains) to boost SCFA production. This supports gut health and may help regulate energy balance and reduce inflammation.

Dysbiosis and increased gut permeability (leaky gut) contribute to obesity through metabolic endotoxemia and low-grade inflammation.

Focus on reducing inflammation through a balanced diet rich in anti-inflammatory foods. Addressing gut health may help manage obesity-related inflammation.

Deficiency or inhibition of the nuclear receptor RORα protects against diet- and age-induced obesity, hepatosteatosis, and insulin resistance by increasing energy expenditure and suppressing pro-inflammatory gene expression in adipose tissue.

This research highlights RORα as a critical regulator of metabolism. While you cannot change your genetics, the discovery of RORα antagonists suggests that future pharmaceutical interventions could potentially mimic the protective effects seen in RORα-deficient mice, such as improved insulin sensitivity and reduced fat storage, by targeting this specific receptor pathway.

Deficiency or inhibition of the nuclear receptor RORγ1 protects against diet-induced insulin resistance and improves glucose tolerance, potentially through mechanisms distinct from RORα.

This research suggests that modulating RORγ1 activity could be a strategy to improve insulin sensitivity. The paper notes that RORγ1 expression positively correlates with adipocyte size and insulin resistance in humans, implying that inhibiting this receptor might help manage type 2 diabetes risk.

RORs (RORα and RORγ) function as intermediaries linking the circadian clock machinery to the regulation of lipid and glucose metabolism, suggesting that circadian disruption may contribute to metabolic syndrome.

Maintaining a consistent sleep schedule and minimizing nighttime light exposure may support healthy metabolic function by aligning with your body's natural circadian rhythms. This alignment helps regulate genes involved in lipid and glucose metabolism, potentially reducing the risk of metabolic syndrome.

Apigenin, a natural flavonoid, ameliorates obesity-related inflammation and metabolic disorders by acting as a selective PPARγ modulator that promotes M2 macrophage polarization without causing the adverse side effects associated with full PPARγ agonists like rosiglitazone.

Apigenin, a flavonoid found in plants like chamomile and parsley, may help reduce obesity-related inflammation and improve metabolic health by modulating the PPARγ receptor. In mouse studies, it reduced inflammatory markers and improved liver and glucose metrics without the weight gain or bone loss seen with prescription drugs like rosiglitazone. While promising, these results are from animal models, and human dosing/effectiveness remains to be established.

Tree nut consumption does not significantly affect fasting insulin or HOMA-IR levels in individuals with type 2 diabetes, although the trend favors improvement.

While tree nuts help lower blood sugar (HbA1c) in people with diabetes, they may not significantly change insulin resistance markers (HOMA-IR) or fasting insulin levels in the short term. This doesn't mean they aren't beneficial, but it highlights that glycemic control and insulin resistance are distinct metrics.

Suprapharmacologic doses of AAS increase muscle mass and strength in eugonadal men through mechanisms involving androgen receptor upregulation, satellite cell activation, and potentially anticatabolic effects, rather than just increased protein synthesis.

The muscle-building effect of high-dose steroids in healthy men is not fully understood but likely involves increasing the number of androgen receptors and activating satellite cells, rather than just speeding up protein synthesis.

Caffeine ingestion (5 mg/kg) does not improve maximal anaerobic power or capacity during the Wingate Test in untrained subjects, despite increasing catecholamine and lactate levels.

If you are not a trained athlete, taking 5mg/kg of caffeine before a short, high-intensity effort (like a 30-second sprint) is unlikely to improve your performance. While it will increase your stress hormones and lactate, it won't make you faster or stronger in that specific context.

Anti-obesity medications targeting monoamine neurotransmitters (re-uptake inhibitors and releasing agents) have a negative benefit-to-harm balance, leading to widespread post-marketing withdrawal due to cardiotoxicity, psychiatric disturbances, and drug abuse.

Avoid centrally acting anti-obesity medications that target monoamine neurotransmitters (e.g., amphetamines, SSRIs used for weight loss) due to high risks of heart problems, psychiatric issues, and addiction. These drugs have been largely withdrawn from the market for these reasons. Focus on diet and lifestyle changes instead, as pharmacological shortcuts have proven unsafe.

Standard interventions that alter energy intake or expenditure (diet or aerobic exercise) cannot distinguish between a unique fixed point model and an invariant manifold model because both yield identical mass change trajectories.

You cannot determine your body's underlying composition dynamics (whether it has a unique set point or flexible states) just by watching how your weight changes when you diet or exercise. Both theoretical models predict the same weight loss curve for energy changes. To understand your body's specific dynamics, you would need to perturb body composition directly (e.g., via resistance training or hormonal changes), not just energy balance.

Advanced stages of MASLD (fibrosis/MASH) causally contribute to heart failure with preserved ejection fraction (HFpEF) through mechanical impediments to hepatic blood flow, reducing right ventricular preload.

If you have advanced liver fibrosis, monitor for signs of heart failure (fatigue, shortness of breath) even if your heart structure looks normal. The stiffness of your liver can mechanically impede blood flow back to the heart, contributing to HFpEF. Managing liver inflammation may help cardiac preload.

Skeletal muscle-derived myonectin confers protection against ischemia-reperfusion injury in the heart, as endurance training reduces infarct size in wild-type mice but not in myonectin-deficient mice.

Endurance training likely protects your heart against certain types of injury (like those during surgery or heart attack) through the release of myonectin. However, human blood tests for myonectin are inconsistent, so this is a protective mechanism you gain through consistent training, not something you can easily monitor or supplement.

Leptin promotes esophageal adenocarcinoma progression by acting directly on esophageal epithelial cells to increase proliferation, invasiveness, and migration, while reducing apoptosis.

There is no direct practical intervention for leptin levels in this context, but reducing visceral fat may lower circulating leptin levels, potentially reducing this specific pro-tumorigenic signaling.

Overexpression of the LAT1 transporter in vitro paradoxically decreases protein synthesis levels and BCKDHα protein content.

This finding is from a cell study, not humans, so it doesn't change your training or diet today. However, it suggests that simply having more of a specific transporter (LAT1) doesn't automatically mean your muscles will build more protein. The body has complex regulatory mechanisms that might actually suppress synthesis if certain transporters are overexpressed artificially.

In severe diabetes, reduced cardiac lipoprotein lipase (LPL) activity forces cardiomyocytes to rely on non-esterified fatty acids (NEFA) from adipose tissue, causing mitochondrial overload, lipid metabolite accumulation, and cardiac lipotoxicity.

In severe diabetes, the heart's ability to process fat from blood lipids (via LPL) drops. This forces the heart to burn fat directly from the blood (NEFA), which it cannot handle efficiently, leading to damage. Treatments must focus on restoring this specific fat-processing pathway in the heart, not just lowering overall blood fat.